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Botulinum ADP-ribosyltransferase C3 modified 21-24 kDa proteins in a guanine nucleotide-dependent 
manner similar to that described for botulinum neurotoxin CI and D. Whereas GTP and GTP~S stimulated 
C3-catalyzed ADP-ribosylation i the absence of Mg a +, in the presence of added Mg 2 + ADP-ribosylation 
was impaired by GTPyS. C3 was about 1000-fold more potent than botulinum C1 neurotoxin i  ADP-ribo- 
sylation of the 21-24 kDa protein(s) in human platelet membranes. Antibodies raised against C3 blocked 
ADP-ribosylation of the 21-24 kDa protein by C3 and neurotoxin C1 but neither cross reacted with neu- 
rotoxin C1 immunoblots nor neutralized the toxicity of neurotoxin CI in mice. The data indicate that the 
ADP-ribosylation of low molecular mass GTP-binding proteins in various eukaryotic ells is not caused 
by botulinum neurotoxins butis due to the action of botulinum ADP-ribosyltransferase C3. The weak enzy- 
matic activities described for botulinum neurotoxins appear to be due to the contamination f CI and D 
preparations with ADP-ribosyltransferase C3. 
ADP-ribosylation; Botulinum ADP-ribosyltransferase C3; Botulinum-neurotoxin C1; Botulinum neurotoxin D; 
GTP-binding protein 
1. INTRODUCTION 
Various strains of Clostridium botufinum pro- 
duce at least eight different oxins which belong to 
the most potent biological active substances so far 
known. Seven of the eight toxins (A, B, C1, D, E, 
F, G) are neurotoxic and block the neurotransmit- 
ter release at cholinergic but also at various other 
synapses by a still unknown mechanism [1]. The 
binary botulinum C2 toxin is not neurotoxic but 
cytotoxic and acts by ADP-ribosylating non- 
muscle actin of the target cell thereby severely 
reducing the ability of actin to polymerize [2]. 
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Recently it has been reported that also botulinum 
neurotoxins C1 and D possess ADP- 
ribosyltransferase activity [3-5]. Both toxins 
reportedly ADP-ribosylate 21-26 kDa GTP- 
binding proteins upposedly involved in exocytosis 
[3-51. 
Previously we described the purification of an 
additional botulinum ADP-ribosyltransferase C3
from the culture filtrates of C. botul inum type C 
[6]. The enzyme has a molecular mass of about 25 
kDa and is, thus, distinct from botulinum 
neurotoxins (150 kDa) and the binary botulinum 
C2 toxin (50 and 100 kDa, component I and II, 
respectively) also produced by C. botul inum type 
C [1,2,6]. The substrate of botulinum ADP- 
ribosyltransferase C3 appears to be 21-24 kDa 
protein(s) found in membranes of human platelets, 
chicken embryo fibroblasts, PC 12-cells, 
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neuroblastoma × glioma hybrid cells, $49 lym- 
phoma cells and various other cell types [6,7]. 
Since C3-catalyzed ADP-ribosylation of the 
eukaryotic protein substrate is regulated by 
guanine nucleotide [7] as reported also for 
neurotoxins C1 and D [4,5] and since all these 
agents are produced by C. botulinum type C we 
studied whether they are structurally and im- 
munologically related. From these studies we con- 
clude that the ADP-ribosylation of low molecular 
mass GTP-binding proteins in various eukaryotic 
cells is not caused by botulinum neurotoxins C1 
and D but by botulinum ADP-ribosyltransferase 
C3. 
formed pellet was washed with ether and dissolved 
in 50 /A electrophoresis buffer. SDS-gel elec- 
trophoresis was performed according to Laemmli 
[11]. Gels were stained with Coomassie blue, de- 
stained and subjected to autoradiography for 48 h. 
Alternatively, after the incubation time of 15 min 
the reactions were stopped by the addition of 400 
~1 of a solution containing SDS (2%, w/v), bovine 
serum albumin (1 mg/ml) and precipitation of the 
proteins with 500/A of trichloroacetic acid (30%, 
w/v). Proteins were collected onto nitrocellulose 
filters. The filters were washed 10 times with 2 ml 
of 6% trichloroacetic acid and placed in scintilla- 
tion fluid for counting of retained radioactivity. 
2. MATERIALS AND METHODS 
2.1. Materials 
Botulinum ADP-ribosyltransferase C3 was 
purified as described [6] from culture filtrate of C. 
botulinum type C strain 4/12 kindly donated by Dr 
Semler (Giegen, FRG). Botulinum C1 neurotoxin 
was purified from C. botulinum type C strain C 
250 (donated by Dr G. Sakaguchi, Osaka, Japan) 
according to the method of Kurazono et al. [8] and 
was kindly donated by Dr J. Frevert (Frankfurt, 
FRG). All nucleotides used were obtained from 
Boehringer (Mannheim, FRG). [32p]NAD was 
prepared as described by Cassel and Pfeuffer [9]. 
2.2. Preparation of human platelet membranes 
Human platelet membranes were isolated as 
described [10], lysed by freezing and thawing in a 
hypotonic buffer containing 10 mM triethanol- 
amine-HC1 (pH 7.4) and 5 mM EDTA. Crude 
platelet membranes were obtained by centrifuga- 
tion of the lysate for 15 min at 30000 x g. The 
pellet was washed twice with hypotonic buffer then 
used for the ADP-ribosylation assay. 
2.3. ADP-ribosylation assay 
ADP-ribosylation was carried out essentially as 
described [6]. The reaction medium contained 10 
mM thymidine, 0.5 mM ATP, 1 mM EDTA, 0.5 
/~M [32p]NAD (0.3-1 /~Ci), the indicated concen- 
trations of C3 and 50 mM triethanolamine-HCl 
(pH 7.4) in a total volume of 100/A. Protein con- 
centration was 50-200/~g/tube. After incubation 
for 15 min at 37°C the reaction was stopped by 
adding 1 ml trichloroacetic acid (20%, w/v). The 
2.4. Immunoblotting 
Immunoblotting was performed according to 
Towbin et al. [12] with rabbit anti-C3 serum 
(1:100), peroxidase-coupled swine IgG to rabbit 
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Fig.1. ADP-ribosylation of human platelet proteins by 
botulinum ADP-ribosyltransferase C3. SDS-poly- 
acrylamide (15°70) gel analysis of radioactive products 
resulting from ADP-ribosylation of human platelet 
membrane proteins by C3 (35 ng) without added MgCI2 
(lanes 1-3) and with MgCI2 (5 mM, lanes 4-6) in the 
absence (lanes 1,4) and presence of GTP (100/~M, lanes 
2,5) and GTPyS (100/~M, lanes 3,6). 
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Table 1 
ADP-ribosylation of the 21 kDa platelet protein by 
botulinum ADP-ribosyltransferase C3 and botulinum 
neurotoxin C1 
ADP-ribosyltrans ferase Activity 
(pmol ADP-ribose/mg 
protein per 5 min) 
C3 (ng/100/A) 
0.4 0.45 
4. 2.6 
40 8.4 
CI (ng/100 ~1) 
70 0.085 
700 0.54 
Human platelet membrane proteins were ADP- 
ribosylated with the indicate concentrations of C3 or C1 
for 30 min as described in section 2 with the exception 
that 1 mM MgC12 were presented and EDTA was omit- 
ted. The radioactivity of the labelled proteins was deter- 
mined by the filter method. The data are means of 
duplicate observations. The amount of ADP-ribose is 
expressed per mg of platelet membrane protein 
IgG (Dakopatts)  as second ant ibody and 
4-ch loro- l -naphtho l  and H202 as peroxidase 
substrate. 
3. RESULTS AND DISCUSSION 
It has been reported that botu l inum neurotoxin 
C1 and D possess ADP-r ibosy l t ransferase ac- 
tivities [3-5] which were speculated to be involved 
in toxin inhibit ion of  exocytosis processes. Both 
toxins reportedly ADP-r ibosy late  identical 21-26 
kDa protein substrates in pheochromocytoma and 
pr imary-cul tured mouse brain or rat brain 
preparat ions [3-5]. ADP-r ibosy lat ion  by these 
neurotoxins was dependent on magnesium ions 
and guanine nucleotides [4,5]. As with botul inum 
neurotoxins,  magnesium ions and guanine nucle- 
otides regulated C3-catalyzed ADP-r ibosy lat ion  of  
21-24 kDa platelet proteins. Fig.1 shows that in 
the absence of  added MgClz and with 1 mM ED- 
TA,  GTP  (100/~M) and GTPyS (100/~M) increased 
the C3-induced labell ing of  21-24 kDa protein(s). 
GMP and ATPTS did not show any effects (not 
shown). In the presence of  MgC12, however, 
GTPTS impaired the ADP-r ibosy lat ion.  In com- 
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Fig.2. Inhibition of the C3-catalyzed ADP-ribosylation by anti-C3 antibodies. Influence of increasing concentrations 
of anti-C3 serum on the C3-induced ADP-ribosylation. (Left) C3 (15 ng) was incubated without and with the indicated 
dilutions of anti-C3 serum (e) or non-immune serum (©) for 30 min at 4°C. Thereafter the ADP-ribosylation of 
platelet proteins was started with the anti-C3 serum mixture in a medium as described above with the exception that 
2 mM MgC12 was present and EDTA was omitted. The radioactivity of labelled proteins was measured by the filter 
method as described. (Right) Autoradiogram of SDS-polyacrylamide (11%) gel analysis of platelet proteins ADP- 
ribosylated as described above with non-immune serum (lane 1) and anti-C3 serum (lane 2) at a dilution of 1:100. 
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paring the ADP-ribosyltransferase activities of 
botulinum neurotoxin C1 and C3, we observed 
that C3 was about 3 orders of magnitude more po- 
tent than purified neurotoxin C1 in labelling the 
21-24 kDa substrate(s) in platelet membranes 
(table 1) or rat brain tissue preparations (not 
shown). Notably, the C1 preparation used was ex- 
tremely toxic in mice (LDs0) about 15 pg/mouse, 
i.p.) while C3 was not toxic even up to 1 #g/mouse. 
In order to exclude the possibility that C3 is an ac- 
tive fragment of botulinum C1 toxin, which was 
not released under the conditions used, we raised 
antibodies against purified botulinum ADP- 
ribosyltransferase C3. The antibodies recognized 
the antigen at a titer of 1:100000. As shown in 
fig.2 antiserum but not preimmune serum blocked 
the ADP-ribosyltransferase activity of C3 in- 
dicating the specificity of the antibodies. In con- 
trast to C3, this antiserum failed to crossreact with 
botulinum neurotoxin C1 indicating that there was 
apparently no structural relation between C3 and 
C1 (fig.3). Furthermore, the anti-C3 serum did not 
affect the toxicity of the neurotoxin in mice studied 
by means of time-to-death determinations (not 
shown). On the other hand, the anti-C3 antibodies 
blocked the weak labelling of the 21 kDa protein 
caused by the botulinum neurotoxin C1 prepara- 
tion (fig.4). In contrast ADP-ribosylation of actin 
by botulinum C2 toxin was not impaired by anti- 
C3 antibodies indicating that the ADP- 
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Fig.4. Impairment of botulinum neurotoxin Cl-induced 
ADP-ribosylation of platelet proteins by anti-C3 an- 
tibodies. SDS-polyacrylamide (15%) gel analysis of 
platelet proteins labelled by botulinum neurotoxin CI 
(1.4#g) pretreated with non-immune serum (lane 1) and 
anti-C3 serum (lane 3) for 1 h at room temperature. 
ADP-ribosylation was performed as described with the 
exception that MgCI2 was 2 mM and EDTA was 
omitted. 
ribosylation reaction was not unspecifically block- 
ed by the antibodies used (not shown). Thus, our 
findings strongly argue against the notion that 
botulinum neurotoxin C1 or an active fragment of 
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Fig.3. SDS gel and immunoblot of ADP-ribosyltransferase C3 and botulinum neurotoxin C1. C1 (l.4#g) and C3 (1.25 
#g) were heated without and with dithiothreitol (DTT, 10 raM) and analyzed by SDS-polyacrylamide gelelectrophoresis 
(SDS gel) and thereafter immunoblotting was performed as described. 
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the neurotoxin ADP-ribosylates the 21-24 kDa 
substrate(s). Taking into consideration the rather 
high concentration (2-100 ~g/ml) of neurotoxins 
used in earlier reports [4-6], our data lead to the 
hypothesis that the ADP-ribosyltransferase ac- 
tivities of botulinum neurotoxins C1 and D are 
merely due to a contamination by C3. 
The nature of the low molecular mass GTP- 
binding protein, modified by C3 is not known at 
present. Several GTP-binding proteins with 
molecular masses of 20-30 kDa have been iden- 
tified recently. Among these are various ras pro- 
teins supposed involved in cell differentiation or 
growth [13]. We have tested H-ras and elongation 
factor Tu, which shows high homology with ras 
but could not find any labelling of these proteins. 
Other ras proteins, the ADP-ribosylating factor 
(ARF) [14], which is necessary for cholera toxin 
action on Gs and the Gp protein [15] purified from 
placenta tissue with still unknown functions re- 
main to be tested. Furthermore, it has recently 
been shown that apparently 4 different low 
molecular mass GTP-binding proteins can be iden- 
tified by [cr-32p]GTP binding in platelets [16]. 
Considering the importance of cholera toxin and 
pertussis toxin for studying the function and role 
of GTP-binding proteins involved in adenylate 
cyclase regulation one can expect that the novel 
ADP-ribosyltransferase C3 will also be very useful 
to distinguish and characterize these low molecular 
mass GTP-binding proteins. Our data, however, 
lend no support to the hypothesis that the in- 
hibitory effects on neurotransmitter release by 
botulinum neurotoxins C1 and D are based on 
ADP-ribosylation of GTP-binding proteins. 
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